伊立替康
医学
加药
卡培他滨
结直肠癌
内科学
基因型
放化疗
胃肠病学
不利影响
毒性
喜树碱
序号38
临床终点
药理学
肿瘤科
癌症
随机对照试验
化学
有机化学
基因
生物化学
作者
Peicheng Jiang,Shuo‐Wen Wang,Chao Li,Jie Fan,Ji Zhu
摘要
Abstract Irinotecan plays a crucial role in the neoadjuvant chemoradiotherapy (nCRT) of rectal cancer, but its optimal dosing is still unclear. In this study, we included 101 eligible patients with the UGT1A1*28 genotype of UGT1A1*1*1 (74.3%) and UGT1A1*1*28 (25.7%) and UGT1A1*6 genotypes of GG (63.4%), GA (32.7%), and AA (3.9%). All patients received preoperative radiotherapy (50 Gy/25 fractions) with concurrent irinotecan (UGT1A1*1*1: 80 mg/m 2 ; UGT1A1*1*28: 65 mg/m 2 ) and capecitabine (CapIri). SN‐38 concentrations were measured at 1.5, 24, and 49 h post‐administration. Patients were divided into four groups (Q1–Q4) based on the SN‐38 concentration. The complete‐response (CR) rate was the primary endpoint. The analysis demonstrated that the 49 h SN‐38 concentration was relatively optimal for predicting efficacy and toxicity. The Q4 group had a significantly higher CR rate than the Q1 group ( p = .019), but also higher rates of adverse events ( p = .009). We screened the recommended 49 h SN‐38, with a 0.5–1.0 ng/mL concentration range. We also validated the correlation between UGT1A1*6 polymorphism and SN‐38 concentration, along with the clinical efficacy of irinotecan. In conclusion, our study identified the relatively optimal timepoint and concentration range for monitoring SN38 concentrations and revealed the clinical significance of UGT1A1*6 and UGT1A1*28 polymorphisms in guiding irinotecan administration, offering meaningful insights for personalised irinotecan dosing.
科研通智能强力驱动
Strongly Powered by AbleSci AI